This document provides guidance for the measurement of lead concentrations in blood and urine, including specimen collection, measurement by graphite furnace atomic absorption spectrometry, anodic stripping voltammetry, and inductively coupled plasma mass spectrometry. It also includes guidelines for quality assurance and quality control, and information on proficiency testing programs and laboratory certification.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org
Measurement Procedures for the Determination of Lead Concentrations in Blood and Urine; Approved Guideline—Second Edition

Volume 33 Number 13

Uttam Garg, PhD, DABCC
Montserrat González Estecha, MD, PhD
Robert L. Jones, PhD
Jennifer Lowry, MD
Nelly Manay, PhD
Robb Morse
Heather Mowers
Patrick J. Parsons, PhD, C. Chem, FRSC
Erlo Roth, MD, MBA, FCAP
Noel V. Stanton, MS
Douglas F. Stickle, PhD, DABCC, FACB

Abstract

Clinical and Laboratory Standards Institute document C40-A2—Measurement Procedures for the Determination of Lead Concentrations in Blood and Urine; Approved Guideline—Second Edition is intended for use by members of the clinical laboratory testing community involved in the collection and measurement of lead in blood and urine. The guideline addresses the clinical significance of lead measurements; specimen collection; and lead determination by graphite furnace atomic absorption spectrometry, anodic stripping voltammetry, and inductively coupled plasma mass spectrometry. It also addresses reference materials, QC procedures, and laboratory policy.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Copyright ©2013 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation


Proposed Guideline
April 1998

Approved Guideline
June 2001

Approved Guideline—Second Edition
October 2013

ISBN 1-56238-891-6 (Print)
ISBN 1-56238-892-4 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)
Contents

Abstract.................................................................................................................................................... i
Committee Membership........................................................................................................................ iii
Foreword.............................................................................................................................................. vii
1 Scope.......................................................................................................................................... 1
2 Standard Precautions.................................................................................................................. 1
3 Terminology............................................................................................................................... 2
  3.1 A Note on Terminology ................................................................................................ 2
  3.2 Definitions .................................................................................................................... 2
  3.3 Abbreviations and Acronyms ....................................................................................... 5
4 Clinical Significance of Lead Concentration Measurements ..................................................... 7
  4.1 Absorption of Lead and Its Internal Distribution Within the Body .............................. 8
  4.2 Toxic Effects of Exposure to Lead in Children and Adults .......................................... 8
  4.3 Concentration of Lead in Blood Deemed Safe for Children/Adults ......................... 11
  4.4 Use of Blood Lead Concentration Measurements as a Marker of Lead Exposure .... 12
  4.5 Use of Urinary Lead Concentration Measurements in the Mobilization Test ............ 13
  4.6 In Vivo X-ray Fluorescence Measurements of Bone Lead ......................................... 13
  4.7 Use and Analysis of Erythrocyte Protoporphyrin ....................................................... 13
  4.8 Reference Intervals for Lead in Blood and Urine ....................................................... 14
5 Measurement Procedures for Lead Concentration ................................................................... 15
  5.1 Early Methods for the Determination of Lead Concentration .................................... 15
  5.2 Flame Atomic Absorption Spectrometry and Methyl Isobutyl Ketone Extraction ..... 15
  5.3 Delves-Cup Flame Atomic Absorption Spectrometry Method ................................... 15
  5.4 Anodic Stripping Voltammetry................................................................................... 16
  5.5 Graphite Furnace Atomic Absorption Spectrometry .................................................. 16
  5.6 Mass Spectrometric Methods ...................................................................................... 17
  5.7 Future Approaches to Blood Lead Concentration Measurements .............................. 20
6 Procedure for Collecting Blood and Urine for Lead Concentration Determination (see
  Section 10.3) ............................................................................................................................ 21
  6.1 Capillary Blood Samples ............................................................................................ 21
  6.2 Procedure for Collecting Venous Blood Samples....................................................... 27
  6.3 Procedure for Collecting Urine Samples .................................................................... 29
7 Procedure for Lead in Blood and Urine by Graphite Furnace Atomic Absorption
  Spectrometry............................................................................................................................ 31
  7.1 Principle of Measurement and Method Summary ...................................................... 31
  7.2 Instrumentation Requirements ................................................................................... 31
  7.3 Reagents and Other Materials ..................................................................................... 34
  7.4 Preparation of Reagents, Calibration Standards, and Samples for Analysis ............ 35
  7.5 Furnace Operation and Maintenance .......................................................................... 38
  7.6 Calculations .................................................................................................................. 39
  7.7 Troubleshooting.......................................................................................................... 40
8 Procedures for Lead in Blood by Anodic Stripping Voltammetry ............................................ 43
  8.1 Method Principle......................................................................................................... 43
  8.2 Instrumentation and Procedure .................................................................................. 44
## Contents (Continued)

9 Reference Materials and Quality Control for Lead in Blood and Urine .........................45
   9.1 Reference Materials ..................................................................................................45
   9.2 Quality Control .........................................................................................................51

10 Laboratory Policy ........................................................................................................53
   10.1 Laboratory Certification and Proficiency Testing ................................................53
   10.2 Follow-up and Rescreening ....................................................................................53
   10.3 General Policies for Lead Analyses (see Section 5) .............................................55

References ..........................................................................................................................58

Appendix A. Laboratory Certification and Proficiency Testing in the United States ..........67
Appendix B. Procedure for Checking Materials and Specimen Collection Supplies for Lead Contamination .............................................................................................................70
Appendix C. Electronic Reporting Policies for US Blood Lead Laboratories ......................78
The Quality Management System Approach .....................................................................80
Related CLSI Reference Materials ....................................................................................81
Foreword

Blood lead (BPb) concentrations are used to assess lead exposure. In the United States in 1991, the Centers for Disease Control and Prevention (CDC) lowered BPb concentrations deemed harmful to children from 25 µg/dL (1.21 µmol/L) to 10 µg/dL (0.48 µmol/L). The CDC estimates that 250,000 US children aged 1 to 5 years have BPb levels greater than 10 µg/dL (0.48 µmol/L). At this lower BPb concentration, the erythrocyte protoporphyrin test, once widely used as a screening test for lead exposure, became redundant due to its poor sensitivity for identifying low lead exposure. The CDC recommends direct measurement of BPb concentration to evaluate lead toxicity. It is now increasingly recognized that concentrations below 10 µg/dL (0.48 µmol/L) have a number of adverse health effects.

In 2012, the CDC Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP) recommended, and the CDC concurred, that the term “blood lead level of concern” of 10 µg/dL (0.48 µmol/L), which was last revised in 1991, be eliminated and replaced with a new reference value for BPb in children 1 to 5 years of age. The ACCLPP recommendation was based on compelling scientific evidence that BPb concentrations less than 10 µg/dL (0.48 µmol/L) are associated with IQ deficits, attention-related behaviors, and poor academic achievement in young children.

With support from the CDC, the ACCLPP recommended that an elevated BPb level be defined as a reference value based on the 97.5th percentile of the BPb distribution among children 1 to 5 years old according to the US National Health and Nutrition Examination Survey (NHANES). The current NHANES 97.5th percentile BPb value is 5 µg/dL (0.24 µmol/L). It was also recommended that the reference value be updated every four years based on the most recent population-based BPb surveys among children. Based on the NHANES data, approximately 450,000 children in the United States have BPb levels higher than 5 µg/dL (0.24 µmol/L). Detailed information on these changes can be found on the CDC website.

The CDC last updated its recommendations for screening young children for lead poisoning in November 1997. The 1997 CDC document addressed specific concerns about the extent to which universal or targeted screening of children should be, or can be, implemented. As part of the release of the 1997 document, the CDC provided specific advice and materials to BPb laboratories that complement the guidelines proposed in this edition of C40. These materials may also be downloaded from the CDC’s website.

In 2012, the ACCLPP also recommended updating the CDC 1997 document regarding appropriate follow-up actions for confirmed, elevated BPb concentrations. The ACCLPP recommendations can be found on the CDC website. The CDC is expected to operationalize the ACCLPP recommendations and publish revised guidance. Information on laboratory accreditation in the United States is also provided in Appendix A, along with details of proficiency testing (PT) (or external quality assessment) programs for BPb in Australia, Canada, the United States, and throughout Europe.

In 1991, established US PT requirements for BPb trueness were tightened to reflect the current improvements in methodology and the lower concentrations of BPb that were deemed harmful. Some laboratories using older methods for BPb were unable to maintain proficiency and were required to improve their method performance. Many were understandably concerned that the analytical technology for making accurate, contamination-free measurements of low concentrations of lead in capillary blood samples did not exist. Since the release of the 1991 CDC statement, it has been shown that current measurement procedures can easily measure BPb concentrations below 10 µg/dL (0.48 µmol/L) with acceptable trueness and precision. The performance of analytical methods at a reference value of 5 µg/dL (0.24 µmol/L) or lower requires evaluation. Measurement trueness continues to improve as evidenced by the performance of participating laboratories in numerous QA and PT programs.
This edition of C40 replaces the first edition of the approved guideline, C40-A, which was published in 2001. The most significant additions since the 2001 edition include:

- The clinical significance of lead concentrations < 10 μg/dL (0.48 μmol/L)
- The definition of elevated BPb in children based on a reference value of 5 μg/dL (0.24 μmol/L)
- General information on sample preparation and analysis by inductively coupled plasma mass spectrometry
- The use of filter paper in blood collection for lead screening

**Key Words**

Analysis, anodic stripping voltammetry, blood, electrothermal atomic absorption spectrometry, graphite furnace, inductively coupled plasma mass spectrometry, lead poisoning, quality control, reference materials, urine
Measurement Procedures for the Determination of Lead Concentrations in Blood and Urine; Approved Guideline—Second Edition

1 Scope

This document is intended for use by members of the clinical laboratory testing community involved in the collection and measurement of lead in blood and urine. A background section on the clinical significance of lead concentration measurements is included to help laboratorians and others understand the context in which these measurements are made. Sample collection and measurement by the three principal measurement procedures currently in routine use are included and listed below.

1. Electrothermal atomic absorption spectrometry (ETAAS), also widely known as graphite furnace atomic absorption spectrometry (GFAAS). Instrumentation for GFAAS is available from many commercial sources. Because instruments vary significantly among manufacturers, a generic measurement procedure is described in some detail.

2. Anodic stripping voltammetry (ASV). Commercial ASV instrumentation specifically for blood lead (BPb) concentration measurement is currently available from a single manufacturer. A detailed ASV procedure, which includes use of a proprietary reagent, is provided by the manufacturer. Details of the commercial ASV method are not duplicated here; rather, the procedure is summarized, and specific recommendations are given that can help with troubleshooting performance problems.

3. Inductively coupled plasma mass spectrometry (ICP-MS). ICP-MS is increasingly used for lead and trace element analysis. It is particularly useful for measuring low lead concentrations (< 10 µg/dL [0.48 µmol/L]), because the newer literature suggests that lead concentrations of < 10 µg/dL (0.48 µmol/L) have detrimental effects, and the reference level for BPb in children has been lowered to 5 µg/dL (0.24 µmol/L). ICP-MS is more sensitive than GFAAS and ASV. Because there are significant variations among makes and models of ICP-MS instrumentation, some general information and recommendations on sample preparation and analysis by ICP-MS are provided.

The document also includes guidelines for QA and QC, and information on proficiency testing (PT) programs and laboratory certification.

The analyst is free to choose which technique best suits the laboratory’s needs, and may modify the recommended procedure to achieve accurate and precise results that meet scientific and regulatory requirements. However, whether following the recommended procedure or a modified version, the analyst is responsible for ensuring that the procedure adopted in the laboratory is validated per the laboratory’s needs and any applicable regulations.

2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. The Centers for Disease Control and Prevention (CDC) addresses this topic in published guidelines that address the daily operations of diagnostic medicine in human and animal medicine while encouraging a culture of safety in the laboratory. For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and...
for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.  

3 Terminology

3.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization for Standardization (ISO), and European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. In light of this, CLSI’s consensus process for development and revision of standards and guidelines focuses on harmonization of terms to facilitate the global application of standards and guidelines.

A hierarchy of terminology was agreed upon, involving ISO (www.iso.org), CEN (www.cen.eu), and CLSI (www.clsi.org).

Essentially, CLSI documents are obliged to harmonize with the most current edition of the International Vocabulary of Metrology – Basic and General Concepts and Associated Terms (VIM) whenever an ambiguity in the interpretation or understanding of terms occurs. In the latest edition, many definitions have become more explicit and understandable, but the language of the VIM is difficult and compact. The VIM deals with general metrology and terminology that should be useful for most disciplines that measure quantities.

The understanding of a few terms has changed during the last decade as the concepts have developed. Particularly, trueness (measurement trueness) is defined as the closeness of agreement between the average of an infinite number of replicate measured quantity values and a reference quantity value; and precision (measurement precision) is defined as closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions. Repeatability and reproducibility are considered to be the extreme measures of precision, with repeatability being the smallest measure (same operator, method, equipment, time, and laboratory) and reproducibility being the largest (different operator, equipment, and laboratory).

The term measurand is used instead of analyte when referring to the quantity intended to be measured (component represented in the name of a measurable quantity) when its use relates to a biological fluid/matrix; the term measurement procedure replaces analytical method and assay for a set of operations, used in the performance of particular measurements according to a given method.

Verification focuses on whether specifications of a measurement procedure can be achieved, whereas validation verifies that the procedure is fit for purpose.

In addition, the term primary reference (measurement) procedure has replaced the term definitive method in C40.

3.2 Definitions

accuracy (measurement) – closeness of agreement between a measured quantity value and a true quantity value of a measurand (JCGM 200:2012); NOTE 1: The concept “measurement accuracy” is not
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (i.e., operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are as follows:

<table>
<thead>
<tr>
<th>Organization</th>
<th>Personnel</th>
<th>Process Management</th>
<th>Nonconforming Event Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Customer Focus</td>
<td>Purchasing and Inventory</td>
<td>Documents and Records</td>
<td>Assessments</td>
</tr>
<tr>
<td>Facilities and Safety</td>
<td>Equipment</td>
<td>Information Management</td>
<td>Assessments</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Continual Improvement</td>
<td></td>
</tr>
</tbody>
</table>

C40-A2 addresses the QSE indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

<table>
<thead>
<tr>
<th>Organization</th>
<th>Customer Focus</th>
<th>Facilities and Safety</th>
<th>Personnel</th>
<th>Purchasing and Inventory</th>
<th>Equipment</th>
<th>Process Management</th>
<th>Documents and Records</th>
<th>Information Management</th>
<th>Nonconforming Event Management</th>
<th>Assessments</th>
<th>Continual Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GP41</td>
<td></td>
<td>GP41</td>
<td>X</td>
<td>x</td>
<td>C38</td>
<td>C24</td>
<td>C38</td>
<td>C24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C24</td>
<td>C38</td>
<td>C24</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination and their respective sequential subprocesses. All laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

C40-A2 addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

<table>
<thead>
<tr>
<th>Preexamination</th>
<th>Examination</th>
<th>Postexamination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination ordering</td>
<td>Sample collection</td>
<td>Sample transport</td>
</tr>
<tr>
<td>GP41</td>
<td>GP16</td>
<td>GP41</td>
</tr>
<tr>
<td>GP41</td>
<td>GP41</td>
<td>GP41</td>
</tr>
<tr>
<td>NBS01</td>
<td>NBS01</td>
<td>NBS01</td>
</tr>
<tr>
<td></td>
<td>GP16</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>GP16</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>NBS01</td>
<td>NBS01</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GP16</td>
</tr>
<tr>
<td></td>
<td>C42</td>
<td>GP16</td>
</tr>
<tr>
<td></td>
<td>C42</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>C42</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NBS01</td>
</tr>
<tr>
<td></td>
<td>GP16</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>GP41</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>NBS01</td>
<td>NBS01</td>
</tr>
<tr>
<td></td>
<td>GP16</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>GP41</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>NBS01</td>
<td>NBS01</td>
</tr>
<tr>
<td></td>
<td>GP16</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>GP41</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>NBS01</td>
<td>NBS01</td>
</tr>
<tr>
<td></td>
<td>GP16</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>GP41</td>
<td>GP41</td>
</tr>
<tr>
<td></td>
<td>NBS01</td>
<td>NBS01</td>
</tr>
</tbody>
</table>

©Clinical and Laboratory Standards Institute. All rights reserved.
Related CLSI Reference Materials


C38-A Control of Preanalytical Variation in Trace Element Determinations; Approved Guideline (1997). This document provides guidelines for patient preparation, specimen collection, transport, and processing for the measurement of trace elements in a variety of biological matrices.

C42-A Erythrocyte Protoporphyrin Testing; Approved Guideline (1996). This document contains recommendations for the measurement, reporting, and interpretation of erythrocyte protoporphyrin using hematofluorometric and extraction measurement methods.

EP05-A2 Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition (2004). This document provides guidance for designing an experiment to evaluate the precision performance of quantitative measurement methods; recommendations on comparing the resulting precision estimates with manufacturers’ precision performance claims and determining when such comparisons are valid; as well as manufacturers’ guidelines for establishing claims.

EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition (2012). This document provides guidance for evaluation and documentation of the detection capability of clinical laboratory measurement procedures (ie, limits of blank, detection, and quantitation), for verification of manufacturers’ detection capability claims, and for the proper use and interpretation of the different detection capability estimates.

GP16-A3 Urinalysis; Approved Guideline—Third Edition (2009). This document addresses procedures for testing urine, including materials and equipment; macroscopic/physical evaluation; chemical analysis; and microscopic analysis.


GP42-A6 Procedures and Devices for the Collection of Diagnostic Capillary Blood Specimens; Approved Standard—Sixth Edition (2008). This document provides a technique for the collection of diagnostic capillary blood specimens, including recommendations for collection sites and specimen handling and identification. Specifications for disposable devices used to collect, process, and transfer diagnostic capillary blood specimens are also included.

M29-A3 Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

NBS01-A6 Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard—Sixth Edition (2013). This document highlights specimen collection methods, discusses acceptable techniques for applying blood drops or aliquots to the filter paper segment of the specimen collection device, and provides instructions on proper specimen handling and transport to ensure quality specimens are consistently obtained for newborn screening analysis.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we’re adding initiatives to bring even more value to our members and customers.

The Key to Quality

Power Forward with this Official Interactive Guide

Fundamentals for implementing a quality management system in the clinical laboratory.

Visit the CLSI U Education Center

Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.

Find Membership Opportunities

See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.

For more information, visit www.clsi.org today.